Kit-Kay Mak1, Mallikarjuna Rao Pichika2, Lee Rong Ling3, Jeremiah Chee Choong Sern3, Seong Chee Yang3, Tan Wan Ying3, Heng Mee Yin3, Moey Shiu Dione3, Ooi Kar Hui3, Agnes Lim Yan Chyi3, Madhu Katyayani Balijepalli4 and Prashant Kesharwani5,*
1MSc Student, School of Postgraduate Studies and Research, International Medical University, Kuala Lumpur, Malaysia
2Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia
3Bachelor of Pharmacy (Hons) Student, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia
4Department of Pharmacology, MAHSA University, Kuala Lumpur, Malaysia
5Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia
*Corresponding Author: Prashant Kesharwani, Lecturer, Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.
Received: December 21, 2017; Published: February 06, 2018
Citation: Prashant Kesharwani., et al. “Comparison of Cisplatin Monotherapy and Cisplatin-Containing Combination Therapy in Term of Survival Rate in Recurrent Cervical Cancer”. Acta Scientific Pharmaceutical Sciences 2.3 (2018).
Cervical cancer is one of the primary cause of death in young female and globally, it is the second most common cancer in female population. Recurrent cervical cancer is the cervical cancer that comes back after the resolving the previous cervical cancer. This review discussed about the comparison of different chemotherapy for recurrent cervical cancer. We have performed a literature search in all available databases for almost all relevant articles regarding chemotherapy of recurrent cervical cancer. The data for this review is mainly composed of studies and articles from 1999 years onwards, inclusive of systematic review, phase III clinical trial and literature review. Cisplatin monotherapy and the cisplatin-containing combinations were evaluated in terms of overall survival, progression-free survival, response rate and toxicity. Based on these factors, the best approach is determined. Cisplatin single therapy has shown greater toxicity of 70% compared to 1.4% in the Cisplatin and Paclitaxel combination (PT) therapy. Cisplatin plus topotecan combination (PO) therapy exhibits hematologic toxicity, which is more frequent and severe compared to cisplatin alone. Neutropenia and leukopenia mostly occur in patients receiving cisplatin and vinorelbine combination (PV) and cisplatin and gemcitabine combination (PG) therapy. Hence, PT therapy is least toxic to the patients. In terms of response rate, progression-free survival, overall survival and degree of toxicity, cisplatin-containing combination therapy is more preferred than cisplatin monotherapy in treating recurrent cervical cancer. In addition to minimal overall survival benefit, PT therapy showed the best response rate, progression-free survival and least toxic among other available combinations.
Keywords: Cervical Cancer; Recurrent Cervical Cancer; Chemotherapy; Cisplatin Monotherapy; Cisplatin/Paclitaxel Combination Therapy
Copyright: © 2018 Prashant Kesharwani., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.